Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

This study has been completed.
Sponsor:
Collaborator:
Eisai Inc.
Information provided by:
Astex Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00041990
First received: July 19, 2002
Last updated: December 12, 2007
Last verified: December 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given